Recombinant manganese peroxidase reduces A2E burden in age-related and stargardt's macular degeneration models

Kelsey J. Moody, Jay Tinklepaugh, Elisabeth Obert, Kris Grohn, Jennifer R. Derosa, Ellie Lumen, Brandon S. Moyer, Scott Campbell, Aaron J. Wolfe, Meegan B. Sleeper, Anthony H. Bianchi, Cheyanne Fisher, Justin Applegate, Emily Leary, Nicholas Leclair, Danique Wortel, Robert Patrick Doyle, Baerbel Rohrer, Adam R. Blanden

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Macular degeneration is hallmarked by retinal accumulation of toxic retinoid species (e.g., A2E) for which there is no endogenous mechanism to eliminate it. This ultimately results in progressive dysfunction and loss of vision either in advanced age for genetically normal patients (age-related macular degeneration) or in adolescence for those with inherited genetic mutations (Stargardt's disease). In this article, we present a proof-of-concept study for an enzyme-based therapy to remove these retinoids, modeled on traditional enzyme replacement therapy. Recombinant manganese peroxidase (rMnP) is produced in Pichia pastoris. In vitro, we demonstrate that rMnP breaks down A2E and other lipofuscin fluorophores with limited cellular toxicity, and as this enzyme is mannosylated, it can be taken up into cells through mannose receptor-dependent endocytosis. In vivo, we demonstrate that rMnP can significantly reduce the A2E burden when administered by intravitreal injections. Together, these data provide encouraging results toward the development of an enzyme-based therapy for macular degeneration and indicate the need for additional work to characterize the molecular mechanism of A2E breakdown and to improve the pharmacological parameters of the enzyme.

Original languageEnglish (US)
Pages (from-to)560-571
Number of pages12
JournalRejuvenation Research
Volume21
Issue number6
DOIs
StatePublished - Dec 1 2018

Fingerprint

manganese peroxidase
Macular Degeneration
Enzyme Therapy
Retinoids
Enzyme Replacement Therapy
Lipofuscin
Intravitreal Injections
Pichia
Poisons
Enzymes
Endocytosis
Pharmacology
Mutation
Stargardt disease 1

Keywords

  • A2E
  • enzyme replacement therapy
  • macular degeneration
  • ophthalmology
  • Stargardt's disease

ASJC Scopus subject areas

  • Aging
  • Geriatrics and Gerontology

Cite this

Moody, K. J., Tinklepaugh, J., Obert, E., Grohn, K., Derosa, J. R., Lumen, E., ... Blanden, A. R. (2018). Recombinant manganese peroxidase reduces A2E burden in age-related and stargardt's macular degeneration models. Rejuvenation Research, 21(6), 560-571. https://doi.org/10.1089/rej.2018.2146

Recombinant manganese peroxidase reduces A2E burden in age-related and stargardt's macular degeneration models. / Moody, Kelsey J.; Tinklepaugh, Jay; Obert, Elisabeth; Grohn, Kris; Derosa, Jennifer R.; Lumen, Ellie; Moyer, Brandon S.; Campbell, Scott; Wolfe, Aaron J.; Sleeper, Meegan B.; Bianchi, Anthony H.; Fisher, Cheyanne; Applegate, Justin; Leary, Emily; Leclair, Nicholas; Wortel, Danique; Doyle, Robert Patrick; Rohrer, Baerbel; Blanden, Adam R.

In: Rejuvenation Research, Vol. 21, No. 6, 01.12.2018, p. 560-571.

Research output: Contribution to journalArticle

Moody, KJ, Tinklepaugh, J, Obert, E, Grohn, K, Derosa, JR, Lumen, E, Moyer, BS, Campbell, S, Wolfe, AJ, Sleeper, MB, Bianchi, AH, Fisher, C, Applegate, J, Leary, E, Leclair, N, Wortel, D, Doyle, RP, Rohrer, B & Blanden, AR 2018, 'Recombinant manganese peroxidase reduces A2E burden in age-related and stargardt's macular degeneration models', Rejuvenation Research, vol. 21, no. 6, pp. 560-571. https://doi.org/10.1089/rej.2018.2146
Moody, Kelsey J. ; Tinklepaugh, Jay ; Obert, Elisabeth ; Grohn, Kris ; Derosa, Jennifer R. ; Lumen, Ellie ; Moyer, Brandon S. ; Campbell, Scott ; Wolfe, Aaron J. ; Sleeper, Meegan B. ; Bianchi, Anthony H. ; Fisher, Cheyanne ; Applegate, Justin ; Leary, Emily ; Leclair, Nicholas ; Wortel, Danique ; Doyle, Robert Patrick ; Rohrer, Baerbel ; Blanden, Adam R. / Recombinant manganese peroxidase reduces A2E burden in age-related and stargardt's macular degeneration models. In: Rejuvenation Research. 2018 ; Vol. 21, No. 6. pp. 560-571.
@article{72b6d20893d64639bbf360cac61daa4b,
title = "Recombinant manganese peroxidase reduces A2E burden in age-related and stargardt's macular degeneration models",
abstract = "Macular degeneration is hallmarked by retinal accumulation of toxic retinoid species (e.g., A2E) for which there is no endogenous mechanism to eliminate it. This ultimately results in progressive dysfunction and loss of vision either in advanced age for genetically normal patients (age-related macular degeneration) or in adolescence for those with inherited genetic mutations (Stargardt's disease). In this article, we present a proof-of-concept study for an enzyme-based therapy to remove these retinoids, modeled on traditional enzyme replacement therapy. Recombinant manganese peroxidase (rMnP) is produced in Pichia pastoris. In vitro, we demonstrate that rMnP breaks down A2E and other lipofuscin fluorophores with limited cellular toxicity, and as this enzyme is mannosylated, it can be taken up into cells through mannose receptor-dependent endocytosis. In vivo, we demonstrate that rMnP can significantly reduce the A2E burden when administered by intravitreal injections. Together, these data provide encouraging results toward the development of an enzyme-based therapy for macular degeneration and indicate the need for additional work to characterize the molecular mechanism of A2E breakdown and to improve the pharmacological parameters of the enzyme.",
keywords = "A2E, enzyme replacement therapy, macular degeneration, ophthalmology, Stargardt's disease",
author = "Moody, {Kelsey J.} and Jay Tinklepaugh and Elisabeth Obert and Kris Grohn and Derosa, {Jennifer R.} and Ellie Lumen and Moyer, {Brandon S.} and Scott Campbell and Wolfe, {Aaron J.} and Sleeper, {Meegan B.} and Bianchi, {Anthony H.} and Cheyanne Fisher and Justin Applegate and Emily Leary and Nicholas Leclair and Danique Wortel and Doyle, {Robert Patrick} and Baerbel Rohrer and Blanden, {Adam R.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1089/rej.2018.2146",
language = "English (US)",
volume = "21",
pages = "560--571",
journal = "Rejuvenation Research",
issn = "1549-1684",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Recombinant manganese peroxidase reduces A2E burden in age-related and stargardt's macular degeneration models

AU - Moody, Kelsey J.

AU - Tinklepaugh, Jay

AU - Obert, Elisabeth

AU - Grohn, Kris

AU - Derosa, Jennifer R.

AU - Lumen, Ellie

AU - Moyer, Brandon S.

AU - Campbell, Scott

AU - Wolfe, Aaron J.

AU - Sleeper, Meegan B.

AU - Bianchi, Anthony H.

AU - Fisher, Cheyanne

AU - Applegate, Justin

AU - Leary, Emily

AU - Leclair, Nicholas

AU - Wortel, Danique

AU - Doyle, Robert Patrick

AU - Rohrer, Baerbel

AU - Blanden, Adam R.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Macular degeneration is hallmarked by retinal accumulation of toxic retinoid species (e.g., A2E) for which there is no endogenous mechanism to eliminate it. This ultimately results in progressive dysfunction and loss of vision either in advanced age for genetically normal patients (age-related macular degeneration) or in adolescence for those with inherited genetic mutations (Stargardt's disease). In this article, we present a proof-of-concept study for an enzyme-based therapy to remove these retinoids, modeled on traditional enzyme replacement therapy. Recombinant manganese peroxidase (rMnP) is produced in Pichia pastoris. In vitro, we demonstrate that rMnP breaks down A2E and other lipofuscin fluorophores with limited cellular toxicity, and as this enzyme is mannosylated, it can be taken up into cells through mannose receptor-dependent endocytosis. In vivo, we demonstrate that rMnP can significantly reduce the A2E burden when administered by intravitreal injections. Together, these data provide encouraging results toward the development of an enzyme-based therapy for macular degeneration and indicate the need for additional work to characterize the molecular mechanism of A2E breakdown and to improve the pharmacological parameters of the enzyme.

AB - Macular degeneration is hallmarked by retinal accumulation of toxic retinoid species (e.g., A2E) for which there is no endogenous mechanism to eliminate it. This ultimately results in progressive dysfunction and loss of vision either in advanced age for genetically normal patients (age-related macular degeneration) or in adolescence for those with inherited genetic mutations (Stargardt's disease). In this article, we present a proof-of-concept study for an enzyme-based therapy to remove these retinoids, modeled on traditional enzyme replacement therapy. Recombinant manganese peroxidase (rMnP) is produced in Pichia pastoris. In vitro, we demonstrate that rMnP breaks down A2E and other lipofuscin fluorophores with limited cellular toxicity, and as this enzyme is mannosylated, it can be taken up into cells through mannose receptor-dependent endocytosis. In vivo, we demonstrate that rMnP can significantly reduce the A2E burden when administered by intravitreal injections. Together, these data provide encouraging results toward the development of an enzyme-based therapy for macular degeneration and indicate the need for additional work to characterize the molecular mechanism of A2E breakdown and to improve the pharmacological parameters of the enzyme.

KW - A2E

KW - enzyme replacement therapy

KW - macular degeneration

KW - ophthalmology

KW - Stargardt's disease

UR - http://www.scopus.com/inward/record.url?scp=85058896570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058896570&partnerID=8YFLogxK

U2 - 10.1089/rej.2018.2146

DO - 10.1089/rej.2018.2146

M3 - Article

C2 - 30516450

AN - SCOPUS:85058896570

VL - 21

SP - 560

EP - 571

JO - Rejuvenation Research

JF - Rejuvenation Research

SN - 1549-1684

IS - 6

ER -